4.8(top 12%)
Impact Factor
5.1(top 12%)
extended IF
93(top 4%)
H-Index
2.2K
authors
2.6K
papers
73K
citations
3.9K
citing journals
35.4K
citing authors

Most Cited Articles of Cytotherapy

TitleYearCitations
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement200611K
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement20051.4K
Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)20131.1K
Adipose-derived adult stem cells: isolation, characterization, and differentiation potential2003834
Yield of human adipose-derived adult stem cells from liposuction aspirates2004534
Immunomodulatory effects of fetal and adult mesenchymal stem cells2003404
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure2006338
The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?2013312
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer2011301
Treatment of patients with advanced cancer with the natural killer cell line NK-922013289
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal2013285
Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration2009283
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial2008279
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials2016278
The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration2016277
Defining the risks of mesenchymal stromal cell therapy2010249
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing2012237
Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature2019220
Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta2004218
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints2013217
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells2009212
Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture2005209
Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components2012207
Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia2014205
Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy2011204